江苏吉贝尔药业股份有限公司关于部分首发募投项目结项并将节余募集资金永久补流、部分首发募投项目调整实施进度的公告

Core Viewpoint - The company has completed the initial public offering (IPO) fundraising project related to the construction of a new research and development center and plans to permanently supplement its working capital with the surplus funds of 28.4987 million yuan [1][3]. Fundraising Basic Situation - The company raised a total of 1,107.161626 billion yuan from the IPO, with a net amount of 1,020.88846119 billion yuan after deducting issuance costs of 86.27316481 million yuan [1][2]. Surplus Fund Situation - The surplus amount of 28.4987 million yuan includes bank interest and cash management income, which will be used to support the company's daily operations and business development needs [3][4]. Project Implementation Progress Adjustment - The company has adjusted the implementation timeline for certain fundraising projects, including the production base construction and the development of new drugs, extending deadlines to ensure compliance with quality management standards [6][7]. Measures for Project Implementation - The company will strictly adhere to relevant regulations and optimize resource allocation to ensure the effective implementation of the fundraising projects [8][9]. Review Procedures and Sponsor Opinions - The board of directors has approved the project adjustments and the use of surplus funds, confirming that the decisions comply with regulatory requirements and do not harm shareholder interests [10][11].